Rosen Comments on Benefits of More FDA-Approved Generic Drugs

31 January 2018 Health Care on Bloomberg Law News
Partner David Rosen was quoted in a Health Care on Bloomberg Law article, “Critics Say Trump’s Drug Price Talk Empty without Actions,” about the FDA approving a record number of generic drugs in 2017 amid speculation that President Trump doesn’t want to lower prescription drug prices.

Rosen said it’s encouraging that drug pricing and generic drugs are on Trump’s mind. He explained that generic drugs “can certainly hold down health-care costs” by giving people access to products that are high quality, therapeutically equivalent and lower cost, and that FDA Commissioner Scott Gottlieb is working to make generic drugs more accessible and to ensure applications are approved in a timely manner.

Related Services

Insights

California Establishes Fund to Combat Wildfire Threats
15 July 2019
Renewable Energy Outlook
There’s No Place Like Home – But Is That a Reasonable Accommodation?
15 July 2019
Labor & Employment Law Perspectives
Beginning Construction Continuity Safe Harbor Extended for National Security Concerns
15 July 2019
Renewable Energy Outlook
Manufacturing MarketTrends | July 2019, Issue 2
12 July 2019
Manufacturing MarketTrends
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ